Table 3 Sub analysis of select endocrine-related symptoms reported in the first 5 years post-diagnosis among extended endocrine therapy users and non-usersa.
From: Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
BCPT symptom scale | Mean (SD) score | Not bothered (score = 0) | Extremely bothered (score = 3.5–4) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Total (n = 450) | eET users (n = 288) | eET non-users (n = 162) | P | eET users (n = 288) | eET non-users (n = 162) | P | eET users (n = 288) | eET non-users (n = 162) | P | |
Weight problems | 1.00 (0.97) | 0.97 (0.93) | 1.07 (1.04) | 0.267 | 68 (23.6%) | 43 (26.5%) | 0.489 | 9 (3.1%) | 6 (3.7%) | 0.743 |
Vaginal problems | 1.06 (1.21) | 1.12 (1.23) | 0.95 (1.17) | 0.168 | 104 (36.1%) | 69 (42.6%) | 0.175 | 24 (8.3%) | 11 (6.8%) | 0.557 |
Muscle problems | 1.03 (1.00) | 1.04 (1.01) | 1.01 (0.98) | 0.811 | 69 (24.0%) | 41 (25.3%) | 0.749 | 10 (3.5%) | 5 (3.1%) | 0.827 |
Hot flashes | 1.22 (1.16) | 1.30 (1.19) | 1.07 (1.09) | 0.050 | 71 (24.7%) | 52 (32.1%) | 0.089 | 22 (7.6%) | 6 (3.7%) | 0.097 |
